Drug Profile
Research programme: myostatin inhibitors - Acceleron
Alternative Names: SHP-619Latest Information Update: 01 Dec 2021
Price :
$50
*
At a glance
- Originator Acceleron Pharma
- Class Recombinant fusion proteins
- Mechanism of Action Myostatin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Duchenne muscular dystrophy
Most Recent Events
- 22 Nov 2021 Acceleron Pharma has been acquired by Merck & Co
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 16 Jul 2016 No recent reports of development identified for preclinical development in Duchenne muscular dystrophy in Canada (SC)